| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() GastroMARK Now Available for Imaging Of GI Tract ST. LOUIS, Mo. and CAMBRIDGE, Mass., April 14 -- GastroMARK(R), a contrast agent for use with magnetic resonance imaging (MRI) of the gastrointestinal tract, is now available to U.S. healthcare professionals. GastroMARK, developed by Advanced Magnetics, Inc. and Mallinckrodt Inc., is the first superparamagnetic oral MRI contrast agent to be marketed in the United States. The agent is designed to be used to mark the bowel and to distinguish the bowel from adjacent abdominal structures in upper regions of the gastrointestinal tract. "GastroMARK(R) is particularly effective because it darkens the bowel in the MR image which is easier to read than other currently available MR and CT contrast agents in which the bowel is brightened," stated Pablo Ros, M.D. F.A.C.R. and associate chairman, Department of Radiology, Magnetic Resonance Imaging, Shands Hospital, University of Florida College of Medicine. The safety and efficacy of GastroMARK(R) was evaluated in clinical trials conducted in the United States. The most frequently reported adverse events were diarrhea and flatulence; a large number of patients also reported these events prior to ingestion of GastroMARK(R). GastroMARK(R) has also been cleared for marketing in western Europe, under the brand name Lumirem(TM). It is being marketed in Europe by Guerbet S.A. of France. Advanced Magnetics, Inc., is a pharmaceutical company involved in the development and manufacture of MRI contrast agents for the diagnosis of cancer and other diseases as well as the development of targeted therapeutics for the treatment of liver diseases and other organ-specific diseases. Mallinckrodt is a producer of analgesic pharmaceuticals, diagnostic imaging agents, medical devices, catalysts, and laboratory and microelectronic chemicals.
|